ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis - A Randomized Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 94
- 主要终点
- Steroid Free Clinical Remission
研究概览
简要总结
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease (IBD) characterized by a multifactorial etiology, a variable involvement of large bowel, and a relapsing-remitting course.
In order to keep the disease in a "quiescent" status and to prevent relapses, a significative percentage of UC patients will remain on long-term drug therapy. However, long-term immunosuppressant therapy is not free of risks and complications: in fact, these therapies have an impact on both healthcare system resources and patients' quality of life; more, there are even concerns regarding the side effects of long-term immunosuppressant therapy.
Over the past 20 years, a considerable amount of evidence was produced to support the immunomodulatory role of the appendix in the development and course of UC: there is a strong inverse relationship between previous appendectomy and development of the UC. One of the proposed theories to justify this link is that the appendix could act as a reservoir for commensal bacteria that can be secreted into the colon, affecting its microbiome and immunological response; another theory describes the appendix as the "priming site" for the cytokine production and the immunological cascade that may trigger inflammation in colon and rectum.
The idea of this study moves from these assumptions: the investigators aim to evaluate the impact of appendectomy in patients with UC who are candidates to the treatment with biologics (Anti TNF-a), because of conventional therapies failure. To further reduce any ethical problems and significantly lower any surgical morbidity, investigators will restrict the study population to only patients with active left-sided colitis, so that the surgery for appendectomy will take place on a non-inflamed cecum.
By undertaking this study, the investigators hope to a) learn more about the role of appendix and the impact of appendectomy in the clinical history of Ulcerative Colitis; b) demonstrate that laparoscopic appendectomy, a relatively simple surgical procedure that can also be performed in day-surgery with a very low expected complication rate, is a treatment that is superior to biological therapy, avoiding patients starting a chronic, long-lasting therapy, with the consequent risk of immunosuppression, and with possible higher costs for the health system in the long term.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 or above
- •Patients with a confirmed diagnosis of left-sided UC (extended up to the mid transverse colon)
- •Patients with active disease refractory to conventional treatment and candidates for anti- TNF-a treatment
- •Patients who have given consent to the surgical procedure
排除标准
- •Patients under the age of 18
- •Lack of diagnostic certainty of Ulcerative Colitis / Crohn's disease diagnostic doubt
- •Patients who previously received appendectomy
- •Patients who have had previous laparotomic abdominal surgery, which could make the appendectomy more complex
- •Patients with Severe Acute Colitis/Toxic Megacolon
- •Patients who have not given their consent to the intervention
- •Patients who receive a different surgical procedure from appendectomy because of intraoperative complications
- •Pregnant patients
研究组 & 干预措施
Group 1
Infliximab
干预措施: Infliximab (Drug)
Group 2
Appendectomy
干预措施: Appendectomy (Procedure)
结局指标
主要结局
Steroid Free Clinical Remission
时间窗: 12 months
Steroid Free Clinical Remission at 3 and 12 months (defined as Partial Mayo score \</=2, with no individual sub-score \>1)
Endoscopic remission
时间窗: 12 months
Endoscopic remission at 3 and 12 months (defined as MAYO CU score \</ = 1)
Assessment of Quality of Life
时间窗: 12 months
Assessment of Quality of Life at 3 and 12 months, through the SF-36 questionnaire (Short-form 36)
次要结局
- Clinical Response(12 months)
- Failure rate(24 months)
- Complication assessment(12 months)
- Histological remission(12 months)
- Immunohistochemical evaluation(12 months)
- Colectomy rate(60 months)
研究者
Gaetano Luglio
Associate Professor
Federico II University
